Published in Int J Cancer on July 01, 2009
Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One (2010) 1.19
miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis (2014) 1.16
In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. PLoS One (2012) 0.88
The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PLoS One (2010) 0.87
New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB J (2010) 0.82
Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression. Oncotarget (2014) 0.82
Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines. J Exp Clin Cancer Res (2013) 0.81
Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation. Oncotarget (2016) 0.78
Telomerase activity in bladder cancer tissue. Exp Ther Med (2010) 0.75
Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev (2005) 15.19
Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res (1997) 4.22
Telomerase and cancer therapeutics. Nat Rev Cancer (2008) 3.46
Antiviral drugs in current clinical use. J Clin Virol (2004) 3.23
Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis (2004) 3.07
Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell (2008) 2.85
Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer (2008) 2.54
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (1997) 2.31
MicroRNA profiling in human medulloblastoma. Int J Cancer (2009) 2.12
Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother (1997) 1.88
A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J (2001) 1.79
Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol (1985) 1.51
Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci U S A (1996) 1.42
Targeting telomerase for cancer therapeutics. Br J Cancer (2008) 1.35
Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res (2008) 1.30
Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother (1999) 1.29
A review of the pharmacokinetics of abacavir. Clin Pharmacokinet (2008) 1.12
Telomerase and its potential for therapeutic intervention. Br J Pharmacol (2007) 1.11
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia (2008) 1.10
Lipomatous medulloblastoma in adults. A distinct clinicopathological entity. Am J Surg Pathol (1996) 1.04
Cellular immortality: a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss. Mol Carcinog (1995) 1.04
Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes. Int J Cancer (2009) 1.04
Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol (2007) 1.03
Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. Lab Invest (1991) 1.02
S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells. J Biol Chem (2007) 1.02
Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation. Acta Pharmacol Sin (2007) 0.99
Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab (2005) 0.96
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob Agents Chemother (2007) 0.94
Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res (2006) 0.94
Molecular analysis of PinX1 in medulloblastomas. Int J Cancer (2004) 0.93
Chemoradiotherapy for brain tumors: current status and perspectives. Int J Clin Oncol (2004) 0.92
Characterization of six new human embryonic stem cell lines (HSF7, -8, -9, -10, -12, and -13) derived under minimal-animal component conditions. Stem Cells Dev (2008) 0.91
Interaction of deoxyguanosine nucleotide analogs with human telomerase. Mol Pharmacol (2000) 0.90
Dual roles of telomere dysfunction in initiation and suppression of tumorigenesis. Exp Cell Res (2008) 0.89
Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth. Cancer Res (2008) 0.89
Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro Oncol (2004) 0.88
Medulloblastomas with extensive posttherapy neuronal maturation. Report of two cases. J Neurosurg (2000) 0.87
The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J Pharmacol Exp Ther (2003) 0.86
TRAP-silver staining, a highly sensitive assay for measuring telomerase activity in tumor tissue and cell lines. Braz J Med Biol Res (2002) 0.85
Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines. Cancer Res (1992) 0.85
Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene (2002) 0.84
All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line. J Neurooncol (2007) 0.84
Telomere dysfunction in human keratinocytes elicits senescence and a novel transcription profile. Exp Cell Res (2008) 0.83
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1998) 0.83
Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res (2000) 0.83
Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett (1996) 0.81
Immortalization of mesenchymal stem cells from bone marrow of rhesus monkey by transfection with human telomerase reverse transcriptase gene. Transplant Proc (2008) 0.80
AIDS in the Third World: how to stop the HIV infection? Verh K Acad Geneeskd Belg (2007) 0.78
New approach for the treatment of medulloblastoma by transfection with glial fibrillary acidic protein gene. Surg Oncol (1996) 0.77
Telomerase activity modulation in the prevention of prostate cancer. Urology (2001) 0.77
[Z-ajoene causes cell cycle arrest at G2/M and decrease of telomerase activity in HL-60 cells]. Zhonghua Zhong Liu Za Zhi (2005) 0.76
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol (2008) 3.21
The vascular endothelium of the adipose tissue gives rise to both white and brown fat cells. Cell Metab (2012) 2.97
Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med (2002) 2.82
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91
From cell-ECM interactions to tissue engineering. J Cell Physiol (2004) 1.91
Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One (2008) 1.90
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.87
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer (2005) 1.81
Leptin is induced in the ischemic cerebral cortex and exerts neuroprotection through NF-kappaB/c-Rel-dependent transcription. Stroke (2008) 1.72
Leptin signaling in breast cancer: an overview. J Cell Biochem (2008) 1.71
Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist (2006) 1.70
From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem (2007) 1.65
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther (2005) 1.65
Cell cycle regulation and neural differentiation. Oncogene (2003) 1.59
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene (2005) 1.53
Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle (2009) 1.50
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Oncology (2011) 1.48
Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol (2007) 1.47
Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med (2008) 1.47
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol (2013) 1.46
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol (2006) 1.45
The occurrence of acute myocardial infarction in Italy: a five-year analysis of hospital discharge records. Aging Clin Exp Res (2010) 1.44
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther (2010) 1.43
Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy. Cancer Biol Ther (2011) 1.42
Integrating role of T antigen, Rb2/p130, CTCF and BORIS in mediating non-canonical endoplasmic reticulum-dependent death pathways triggered by chronic ER stress in mouse medulloblastoma. Cell Cycle (2012) 1.41
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer (2011) 1.39
The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade. J Biol Chem (2001) 1.37
Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res (2006) 1.34
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem (2005) 1.33
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 1.33
Activation of MyoD-dependent transcription by cdk9/cyclin T2. Oncogene (2002) 1.33
Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle (2008) 1.32
Advantages and limitations of microarray technology in human cancer. Oncogene (2003) 1.30
Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res (2008) 1.30
Smart materials as scaffolds for tissue engineering. J Cell Physiol (2005) 1.30
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget (2013) 1.26
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res (2013) 1.23
HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res (2004) 1.23
CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci U S A (2010) 1.21
Lung Cancer: Are we up to the Challenge? Curr Genomics (2010) 1.21
Scaffold's surface geometry significantly affects human stem cell bone tissue engineering. J Cell Physiol (2008) 1.20
Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol (2003) 1.20
Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol (2008) 1.19
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. Eur J Cancer (2011) 1.19
Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene (2002) 1.19
Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. Clin Cancer Res (2005) 1.18
Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3beta. J Biol Chem (2006) 1.18
pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene (2003) 1.17
Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene (2004) 1.16
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
The gap between the physiological and therapeutic roles of mesenchymal stem cells. Med Res Rev (2014) 1.15
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res (2004) 1.13
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol (2004) 1.11
Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem (2005) 1.10
Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res (2004) 1.08
Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene (2003) 1.08
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 1.07
Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. Biochem J (2012) 1.06
Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300. Oncogene (2004) 1.06
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
The tumor suppressor role of CTCF. J Cell Physiol (2012) 1.06
In vivo phenotyping of the ob/ob mouse by magnetic resonance imaging and 1H-magnetic resonance spectroscopy. Obesity (Silver Spring) (2006) 1.05
Human polyomaviruses and brain tumors. Brain Res Brain Res Rev (2005) 1.04
In vitro senescence of rat mesenchymal stem cells is accompanied by downregulation of stemness-related and DNA damage repair genes. Stem Cells Dev (2009) 1.03
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol (2014) 1.02
Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol (2007) 1.02
Cdk9 phosphorylates p53 on serine 392 independently of CKII. J Cell Physiol (2006) 1.02
The retinoblastoma family: twins or distant cousins? Genome Biol (2002) 1.02
Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J (2003) 1.02
Sensory or sympathetic white adipose tissue denervation differentially affects depot growth and cellularity. Am J Physiol Regul Integr Comp Physiol (2004) 1.02
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol (2014) 1.02
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res (2009) 1.02
Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer (2008) 1.01
Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells. J Cell Sci (2007) 1.01
Analysis of a mutant p53 protein arising in a medulloblastoma from a mouse transgenic for the JC virus early region. Anticancer Res (2007) 1.01
Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci U S A (2004) 1.01
Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol (2005) 1.00
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther (2006) 1.00
Bartonella: emerging pathogen or emerging awareness? Int J Infect Dis (2008) 0.99
Silencing of RB1 but not of RB2/P130 induces cellular senescence and impairs the differentiation potential of human mesenchymal stem cells. Cell Mol Life Sci (2013) 0.99
CDK9: from basal transcription to cancer and AIDS. Cancer Biol Ther (2002) 0.98
Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype. Exp Mol Pathol (2012) 0.97
Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene (2003) 0.97
Epigenetic modulation of estrogen receptor-alpha by pRb family proteins: a novel mechanism in breast cancer. Cancer Res (2007) 0.97
Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells. J Cell Physiol (2005) 0.97
NSP 5a3a: a potential novel cancer target in head and neck carcinoma. Oncotarget (2010) 0.97